PTH(1 ‐34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology
This study aimed to characterize longitudinal effects of representative anabolic (parathyroid hormone, PTH) and anti‐catabolic (zoledronic acid, ZA) drugs on skeletal morphology, mechanical strength, and growth in juvenile mice. BALB/cJ mice aged four weeks were given PTH(1–34) or vehicle (control) daily for eight weeks, or four weekly doses of ZA, and evaluated at time points 0–26 weeks after treatment initiation. There were no enduring differences in body length or mass between treatment groups. ZA increased femur size as early as week 0, including increased distal femur bone volume and diaphyseal cross‐sectional area, persisting through week 26. PTH treatment only transiently increased bone size, including distal femur volume at weeks 4‐12. ZA decreased diaphyseal cortical tissue mineral density (TMD) at 12–26 weeks vs. controls; PTH decreased TMD only at 2 weeks (vs. controls). ZA increased bending strength at 0–12 weeks and flexural strength at week 4 (vs. controls), but decreased flexural strength and modulus at week 26. PTH treatment increased bending strength only at 4 weeks, and did not affect flexural strength. Overall, ZA rapidly and persistently increased femur strength and size, but compromised bone material quality long‐term. In healthy juvenile mice, limited‐duration PTH treatment did not exert a strong anabolic effect, and had no adverse effects on femur strength, morphology, or growth. This article is protected by copyright. All rights reser...
Source: Journal of Orthopaedic Research - Category: Orthopaedics Authors: Christopher M. Bartlow, Megan E. Oest, Kenneth A. Mann, Nicholas D. Zimmerman, Bilal B. Butt, Timothy A. Damron Tags: Research Article Source Type: research